Skip to Content

Hepatic Fibrosis


Jesse M. Civan

, MD, Thomas Jefferson University Hospital

Last full review/revision Dec 2019| Content last modified Dec 2019

Hepatic fibrosis is overly exuberant wound healing in which excessive connective tissue builds up in the liver. The extracellular matrix is overproduced, degraded deficiently, or both. The trigger is chronic injury, especially if there is an inflammatory component. Fibrosis itself causes no symptoms but can lead to portal hypertension (the scarring distorts blood flow through the liver) or cirrhosis (the scarring results in disruption of normal hepatic architecture and liver dysfunction). Diagnosis is based on liver biopsy. Treatment involves correcting the underlying condition when possible.

In hepatic fibrosis, excessive connective tissue accumulates in the liver; this tissue represents scarring in response to chronic, repeated liver cell injury. Commonly, fibrosis progresses, disrupting hepatic architecture and eventually function, as regenerating hepatocytes attempt to replace and repair damaged tissue. When such disruption is widespread, cirrhosis is diagnosed.

Etiology of Hepatic Fibrosis

Various types of chronic liver injury can cause fibrosis (see table Disorders and Drugs That Can Cause Hepatic Fibrosis). Self-limited, acute liver injury (eg, acute viral hepatitis A), even when fulminant, does not necessarily distort the scaffolding architecture and hence does not cause fibrosis, despite loss of hepatocytes. In its initial stages, hepatic fibrosis can regress if the cause is reversible (eg, with viral clearance). After months or years of chronic or repeated injury, fibrosis becomes permanent. Fibrosis develops even more rapidly in mechanical biliary obstruction.

Disorders and Drugs That Can Cause Hepatic Fibrosis

Categories of Disorders

Specific Examples

Disorders with direct hepatic effects

Autoimmune hepatitis

Certain storage diseases and inborn errors of metabolism

Congenital hepatic fibrosis


Nonalcoholic steatohepatitis (NASH)

Primary biliary cholangitis (PBC)

Primary sclerosing cholangitis (PSC)

Disorders affecting hepatic blood flow

Budd-Chiari syndrome

Heart failure

Hepatic veno-occlusive disease

Portal vein thrombosis

Drugs and chemicals with hepatic effects









Disorders that cause mechanical obstruction

Scarring due to prior liver surgery

Bile duct strictures due to impacted gallstones

* Most common causes.

† Sometimes caused by pyrrolizidine alkaloids, present in herbal products such as bush teas.

Pathophysiology of Hepatic Fibrosis

Activation of the hepatic perivascular stellate cells (Ito cells, which store fat) initiates fibrosis. These and adjacent cells proliferate, becoming contractile cells termed myofibroblasts. These cells produce excessive amounts of abnormal matrix (consisting of collagen, other glycoproteins, and glycans) and matricellular proteins. Kupffer cells (resident macrophages), injured hepatocytes, platelets, and leukocytes aggregate. As a result, reactive oxygen species and inflammatory mediators (eg, platelet-derived growth factor, transforming growth factors, connective tissue growth factor) are released. Thus, stellate cell activation results in abnormal extracellular matrix, both in quantity and composition.

Myofibroblasts, stimulated by endothelin-1, contribute to increased portal vein resistance and increase the density of the abnormal matrix. Fibrous tracts join branches of afferent portal veins and efferent hepatic veins, bypassing the hepatocytes and limiting their blood supply. Hence, fibrosis contributes both to hepatocyte ischemia (causing hepatocellular dysfunction) and portal hypertension. The extent of the ischemia and portal hypertension determines how the liver is affected. For example, congenital hepatic fibrosis affects portal vein branches, largely sparing the parenchyma. The result is portal hypertension with sparing of hepatocellular function.

Symptoms and Signs of Hepatic Fibrosis

Hepatic fibrosis itself does not cause symptoms. Symptoms may result from the disorder causing fibrosis or, once fibrosis progresses to cirrhosis, from complications of portal hypertension. These symptoms include jaundice, variceal bleeding, ascites, and portosystemic encephalopathy. Cirrhosis can result in hepatic insufficiency and potentially fatal liver failure.

Diagnosis of Hepatic Fibrosis

  • Clinical evaluation
  • Sometimes blood tests and/or noninvasive imaging tests
  • Sometimes liver biopsy

Hepatic fibrosis is suspected if patients have known chronic liver disease (eg, chronic viral hepatitis C or chronic hepatitis B, alcoholic liver disease) or if results of liver tests are abnormal; in such cases, tests are done to check for fibrosis and, if fibrosis is present, to determine its severity (stage). Knowing the stage of fibrosis can guide medical decisions. For example, screening for hepatocellular carcinoma and for gastroesophageal varices is indicated if cirrhosis is confirmed, but it is generally not indicated for mild or moderate fibrosis. Assessment of the degree of hepatic fibrosis helps assess the prognosis of patients with chronic viral hepatitis. However, since the widespread availability of direct-acting antiviral drugs, knowing the degree of fibrosis has become much less important in deciding when to initiate antiviral therapy.

Tests used to stage fibrosis include noninvasive imaging tests, blood tests, liver biopsy, and newer tests that assess liver stiffness.

Noninvasive imaging tests include conventional ultrasonography, CT, and MRI. These tests can detect evidence of cirrhosis and portal hypertension, such as liver surface nodularity, splenomegaly, and varices. However, they are not sensitive for moderate or even advanced fibrosis and may fail to detect some cases of cirrhosis if splenomegaly and varices are absent. Although fibrosis may appear as altered echogenicity on ultrasonography or heterogeneity of signal on CT, these findings are nonspecific and may indicate only liver parenchymal fat.

Newer acoustic technologies can increase the accuracy of ultrasonography and MRI for detecting fibrosis or early cirrhosis; they include

  • Ultrasound elastography
  • Magnetic resonance elastography
  • Acoustic radiation force impulse imaging

For these tests, acoustic vibrations are applied to the abdomen with a probe. How rapidly these vibrations are transmitted through liver tissue indicates how stiff (ie, fibrosed) the liver is. However, certain other conditions besides fibrosis also increase liver stiffness, including severe active hepatitis, increased right heart pressures, and the postprandial state. Also, these techniques have not been validated in pregnant patients. Thus, use of these techniques is typically not recommended in patients with one of these conditions.

Liver biopsy remains the gold standard for diagnosing and staging hepatic fibrosis and for diagnosing the underlying liver disorder causing fibrosis. However, liver biopsy is invasive, resulting in a 10 to 20% risk of minor complications (eg, postprocedural pain) and a 0.5 to 1% risk of serious complications (eg, significant bleeding). Also, liver biopsy is limited by sampling error and imperfect interobserver agreement in interpretation of histologic findings. Thus, liver biopsy may not always be done. Liver biopsy is usually not done solely for staging of hepatic fibrosis unless different noninvasive tests yield discordant results.

Blood tests include commercially available panels that combine indirect markers (eg, serum bilirubin) and direct markers of hepatic function. Direct markers are substances involved in the pathogenesis of extracellular matrix deposition or cytokines that induce extracellular matrix deposition. These panels are best used to distinguish between 2 levels of fibrosis: absent to minimal vs moderate to severe; they do not accurately differentiate between degrees of moderate to severe fibrosis. Therefore, if fibrosis is suspected, one approach is to start with one of these panels and then do liver biopsy only if the panel indicates that fibrosis is moderate to severe.

Which tests are done may depend on the degree of clinical suspicion, based on clinical evaluation, including liver test results. For example, noninvasive blood tests may be used to determine whether biopsy is indicated; in some of these cases, imaging tests may not be needed.

Treatment of Hepatic Fibrosis

  • Treatment of cause

Because fibrosis represents a response to hepatic damage, primary treatment should focus on the cause (removing the basis of the liver injury). Such treatment may include antiviral drugs to eliminate hepatitis B virus or hepatitis C virus in chronic viral hepatitis, abstaining from alcohol in alcoholic liver disease, weight loss in patients with nonalcoholic steatohepatitis (NASH), removing heavy metals such as iron in hemochromatosis or copper in Wilson disease, and decompressing bile ducts in biliary obstruction. Such treatments may stop the fibrosis from progressing and, in some patients, also reverse some of the fibrotic changes.

Treatments aimed at reversing the fibrosis are usually too toxic for long-term use (eg, corticosteroids, penicillamine) or have no proven efficacy (eg, colchicine). Other antifibrotic treatments are under study. Silymarin, present in milk thistle, is a popular alternative medicine used to treat hepatic fibrosis. It appears to be safe (except when combined with certain drugs to treat hepatitis C) but lacks efficacy.

Key Points

  • Self-limited, acute liver injury (eg, due to acute viral hepatitis A), even when fulminant, tends not to cause fibrosis.
  • The most common causes of hepatic fibrosis are hepatitis B and C and alcohol abuse.
  • Fibrosis does not cause symptoms unless it progresses to cirrhosis.
  • Liver biopsy, although imperfect, is the gold standard diagnostic test but has been increasingly supplanted by noninvasive alternatives.
  • Noninvasive testing, including ultrasound elastography and magnetic resonance elastography, is becoming increasingly important.
  • Treat the cause of fibrosis.

Drugs Mentioned In This Article

Drug Name Select Trade
Chlorpromazine No US brand name
penicillamine CUPRIMINE
Methotrexate OTREXUP
Amiodarone CORDARONE
colchicine COLCRYS
Methyldopa No brand name
Isoniazid LANIAZID

Copyright © 2022 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer